Referred to the House Committee on Energy and Commerce.
The bill directs HHS/FDA to harmonize human-subject protection regulations to better include pregnant and lactating women in clinical research, requires an HHS public education campaign with $5 million annually for FY2027–2031, and tasks NICHD/NIH with a prioritized research program, reporting, and appropriations authority for FY2027–2031.
Focused, technocratic bill with bipartisan appeal and modest costs; success depends on appropriations follow‑through and Senate scheduling.
Relative to its intended legislative type, this bill is a substantive policy measure that establishes regulatory harmonization duties, a funded public education campaign, and a NICHD research prioritization program with reporting requirements and identified timelines; its design is mostly coherent but leaves some implementation and resourcing details unspecified.
Support versus concern over expanded federal role in research
Support versus concern over expanded federal role in research
Likely supportive.
The bill addresses long-standing evidence gaps about medication safety in pregnancy and lactation, and it funds outreach and prioritized research focused on maternal and infant health.
It aligns with equity-focused goals to reduce maternal morbidity, especially in high-risk populations.
Cautiously favorable.
The bill addresses a concrete data problem and creates processes, timelines, and reporting, but leaves some funding and implementation details vague.
A centrist would weigh benefits against potential regulatory burden and budgetary tradeoffs.
Skeptical.
While acknowledging improved data could help clinicians, this persona worries about expanded federal involvement in research, increased regulation, and potential taxpayer costs.
Concerns include liability, pressure on women to enroll, and unclear funding burdens.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Focused, technocratic bill with bipartisan appeal and modest costs; success depends on appropriations follow‑through and Senate scheduling.
The bill has not accumulated any surfaced votes yet.
Support versus concern over expanded federal role in research
Focused, technocratic bill with bipartisan appeal and modest costs; success depends on appropriations follow‑through and Senate scheduling.
Relative to its intended legislative type, this bill is a substantive policy measure that establishes regulatory harmonization duties, a funded public education campaign, and a NICHD research prioritization program with…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.